Keyphrases
PARP Inhibitor (PARPi)
100%
Breast Cancer Brain Metastasis
100%
Triple-negative Breast Cancer
83%
Pharmacologic
50%
Clinical Trials
50%
Preclinical Modeling
40%
University of North Carolina
33%
Career Goals
33%
Clinical Trial Design
33%
Nanoparticles
33%
Breast Cancer
33%
Anticancer Agents
33%
Pharmacology
33%
Efficacy Study
33%
Central Nervous System Delivery
20%
Translational Trial
20%
Triple-negative Disease
20%
Clinical Approach
20%
Clinical Trial Execution
20%
Novel Agents
20%
Brain Metastases
20%
Interprofessional Collaboration
20%
Breast Cancer Model
20%
Breast Cancer Biology
20%
Medical Oncologist
20%
Clinical Trial Data
20%
Trial Design
16%
Therapeutic Potential
16%
Translational Research
16%
Blood-brain Barrier
16%
Clinical Translational
16%
Murine Model
16%
Career Development
16%
Team Environment
16%
Collaborative Research
16%
Career Development Awards
16%
Clinical Trial Implementation
16%
Mentorship
16%
Training Development
16%
Institutional Environment
16%
Research Professionals
16%
Professional Development
16%
Professional Skills
16%
Associate Professor
16%
Interdisciplinary Research Teams
16%
Comprehensive Cancer Center
16%
Miller
16%
Patients with Breast Cancer
16%
Multicenter Clinical Trial
16%
Research Environment
16%
Development Activities
16%
Nanoparticle Formulation
16%
Multicenter Trial
16%
Physician-scientist
16%
Assure
16%
Research Training
16%
Oncohematology
16%
Medicine and Dentistry
Brain Metastasis
100%
Poly ADP Ribose Polymerase
100%
Triple Negative Breast Cancer
83%
Breast Cancer
69%
Clinical Trial
69%
Nanoparticle
41%
Efficacy Study
27%
Anticarcinogen
27%
Disease
27%
Clinical Trial Design
27%
Central Nervous System Delivery
16%
PARP Inhibitor
16%
Medical Decision Making
16%
Cancer Model
13%
Blood Brain Barrier
13%
Clinical Translational Research
13%
Division
13%
Medicine
13%
Hematology
13%
Oncology
13%
Cancer Pathobiology
13%
Chemotherapy
13%
Oncologist
13%
Malignant Neoplasm
13%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Metastasis
100%
Triple Negative Breast Cancer
83%
Clinical Trial
69%
Breast Cancer
69%
Nanoparticle
41%
Clinical Trial Design
33%
Anticarcinogen
27%
Disease
27%
Efficacy Study
27%
Central Nervous System Delivery
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Malignant Neoplasm
13%
Blood-Brain Barrier
13%
Cancer Model
13%